FY2025 Earnings Forecast for ELAN Issued By Leerink Partnrs

Elanco Animal Health Incorporated (NYSE:ELAN) – Stock analysts at Leerink Partnrs boosted their FY2025 earnings per share estimates for Elanco Animal Health in a research report issued to clients and investors on Thursday, July 17th. Leerink Partnrs analyst D. Clark now anticipates that the company will earn $0.85 per share for the year, up from their previous estimate of $0.84. Leerink Partnrs has a “Strong-Buy” rating on the stock. The consensus estimate for Elanco Animal Health’s current full-year earnings is $0.91 per share. Leerink Partnrs also issued estimates for Elanco Animal Health’s Q4 2025 earnings at $0.15 EPS and FY2026 earnings at $0.95 EPS.

ELAN has been the subject of a number of other research reports. Leerink Partners upgraded Elanco Animal Health from a “market perform” rating to an “outperform” rating and set a $18.00 target price for the company in a report on Thursday. Stifel Nicolaus upped their target price on Elanco Animal Health from $16.00 to $17.00 and gave the company a “buy” rating in a report on Wednesday, July 2nd. William Blair upgraded Elanco Animal Health from a “market perform” rating to an “outperform” rating in a report on Thursday, June 26th. Finally, Wall Street Zen upgraded Elanco Animal Health from a “hold” rating to a “buy” rating in a report on Saturday, July 5th. Two research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, Elanco Animal Health currently has an average rating of “Moderate Buy” and an average price target of $16.00.

Elanco Animal Health Price Performance

Shares of Elanco Animal Health stock opened at $14.78 on Friday. The business’s 50-day moving average price is $13.82 and its 200-day moving average price is $11.79. The company has a current ratio of 2.71, a quick ratio of 1.46 and a debt-to-equity ratio of 0.68. Elanco Animal Health has a 12 month low of $8.02 and a 12 month high of $15.78. The firm has a market capitalization of $7.34 billion, a PE ratio of 19.97, a price-to-earnings-growth ratio of 2.92 and a beta of 1.67.

Elanco Animal Health (NYSE:ELAN) last issued its quarterly earnings results on Wednesday, May 7th. The company reported $0.37 EPS for the quarter, beating analysts’ consensus estimates of $0.31 by $0.06. The firm had revenue of $1.19 billion for the quarter, compared to analysts’ expectations of $1.17 billion. Elanco Animal Health had a return on equity of 7.54% and a net margin of 8.43%. The business’s revenue for the quarter was down 1.0% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.34 EPS.

Institutional Investors Weigh In On Elanco Animal Health

A number of hedge funds have recently made changes to their positions in the company. Bfsg LLC lifted its position in shares of Elanco Animal Health by 5.1% in the second quarter. Bfsg LLC now owns 26,973 shares of the company’s stock worth $385,000 after buying an additional 1,321 shares in the last quarter. GAMMA Investing LLC lifted its position in shares of Elanco Animal Health by 540.4% in the second quarter. GAMMA Investing LLC now owns 7,557 shares of the company’s stock worth $108,000 after buying an additional 6,377 shares in the last quarter. Mitchell & Pahl Private Wealth LLC lifted its position in shares of Elanco Animal Health by 16.9% in the second quarter. Mitchell & Pahl Private Wealth LLC now owns 53,180 shares of the company’s stock worth $759,000 after buying an additional 7,691 shares in the last quarter. Wealth Enhancement Advisory Services LLC raised its position in Elanco Animal Health by 8.9% during the second quarter. Wealth Enhancement Advisory Services LLC now owns 11,516 shares of the company’s stock valued at $169,000 after purchasing an additional 944 shares during the period. Finally, Westbourne Investments Inc. purchased a new stake in Elanco Animal Health during the second quarter valued at approximately $170,000. 97.48% of the stock is currently owned by hedge funds and other institutional investors.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.